Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
The pharmacological mechanisms underlying the hypolocomotion induced by intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) injections of cholecystokinin octapeptide sulphated (CCK) in the mouse were examined using selective CCKA and CCKB receptor antagonists. Locomotor activity was measured...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1991
|
| _version_ | 1797061257814081536 |
|---|---|
| author | O'Neill, M Dourish, C Iversen, S |
| author_facet | O'Neill, M Dourish, C Iversen, S |
| author_sort | O'Neill, M |
| collection | OXFORD |
| description | The pharmacological mechanisms underlying the hypolocomotion induced by intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) injections of cholecystokinin octapeptide sulphated (CCK) in the mouse were examined using selective CCKA and CCKB receptor antagonists. Locomotor activity was measured in photocell cages. CCK (10 micrograms/kg i.p.) significantly reduced activity in mice tested in the afternoon but not in the morning, indicating a circadian variation in the effect of the peptide. The hypolocomotion induced by i.p. injection of 10 micrograms/kg CCK and i.c.v. injection of 3.5 micrograms CCK was reversed by the selective CCKA antagonist devazepide, but not by the selective CCKB antagonist L-365,260. This suggests that CCK-induced hypolocomotion is mediated by CCKA receptors. Larger doses of CCK were required to induce hypolomotion when injected i.c.v. (3.5 micrograms per mouse) than when given i.p. (10 micrograms/kg i.e. 0.2 microgram per mouse). Furthermore the latency to onset of the hypolocomotion after i.c.v. injection of CCK was longer than after i.p. injection of CCK. These data suggest that the sedative action of i.c.v. CCK may be due to leakage of the peptide from the brain and subsequent activation of peripheral CCKA receptors. However a role for CCKA receptors in the CNS in mediating hypolocomotion induced by i.c.v. injection of CCK cannot be ruled out on the basis of the present data. |
| first_indexed | 2024-03-06T20:28:30Z |
| format | Journal article |
| id | oxford-uuid:303e143a-450c-4461-9bc7-328af9d21bba |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:28:30Z |
| publishDate | 1991 |
| record_format | dspace |
| spelling | oxford-uuid:303e143a-450c-4461-9bc7-328af9d21bba2022-03-26T13:00:16ZHypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:303e143a-450c-4461-9bc7-328af9d21bbaEnglishSymplectic Elements at Oxford1991O'Neill, MDourish, CIversen, SThe pharmacological mechanisms underlying the hypolocomotion induced by intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) injections of cholecystokinin octapeptide sulphated (CCK) in the mouse were examined using selective CCKA and CCKB receptor antagonists. Locomotor activity was measured in photocell cages. CCK (10 micrograms/kg i.p.) significantly reduced activity in mice tested in the afternoon but not in the morning, indicating a circadian variation in the effect of the peptide. The hypolocomotion induced by i.p. injection of 10 micrograms/kg CCK and i.c.v. injection of 3.5 micrograms CCK was reversed by the selective CCKA antagonist devazepide, but not by the selective CCKB antagonist L-365,260. This suggests that CCK-induced hypolocomotion is mediated by CCKA receptors. Larger doses of CCK were required to induce hypolomotion when injected i.c.v. (3.5 micrograms per mouse) than when given i.p. (10 micrograms/kg i.e. 0.2 microgram per mouse). Furthermore the latency to onset of the hypolocomotion after i.c.v. injection of CCK was longer than after i.p. injection of CCK. These data suggest that the sedative action of i.c.v. CCK may be due to leakage of the peptide from the brain and subsequent activation of peripheral CCKA receptors. However a role for CCKA receptors in the CNS in mediating hypolocomotion induced by i.c.v. injection of CCK cannot be ruled out on the basis of the present data. |
| spellingShingle | O'Neill, M Dourish, C Iversen, S Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. |
| title | Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. |
| title_full | Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. |
| title_fullStr | Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. |
| title_full_unstemmed | Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. |
| title_short | Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. |
| title_sort | hypolocomotion induced by peripheral or central injection of cck in the mouse is blocked by the ccka receptor antagonist devazepide but not by the cckb receptor antagonist l 365 260 |
| work_keys_str_mv | AT oneillm hypolocomotioninducedbyperipheralorcentralinjectionofcckinthemouseisblockedbythecckareceptorantagonistdevazepidebutnotbythecckbreceptorantagonistl365260 AT dourishc hypolocomotioninducedbyperipheralorcentralinjectionofcckinthemouseisblockedbythecckareceptorantagonistdevazepidebutnotbythecckbreceptorantagonistl365260 AT iversens hypolocomotioninducedbyperipheralorcentralinjectionofcckinthemouseisblockedbythecckareceptorantagonistdevazepidebutnotbythecckbreceptorantagonistl365260 |